pylori has the ability to neutralize the acidity of its environment in the gut, which allows it to proliferate and survive
acute pancreatitis, with an additional positive impact on concomitant gastroduodenal pathology
Practitioners unable or unwilling to discuss potential complications have not done their homework
Thats just a theoretical risk at this pointbut thats the kind of risk that we have clinical trials for
With 2024 as the year when the AOM market took shape, and 2026 a pivotal year that will define future competitive dynamics as the next wave of AOMs launch, and when the first off patent semaglutide likely becomes available in some countries, it is easy to dismiss 2025 as an uneventful transition
A Conceptual Model of Food Cue Reactivity - PMC - PubMed Central, accessed April 22, 2025, GLP1 receptor agonists for the treatment of obesity: Role as a promising approach, accessed April 22, 2025, GLP-1 and the Neurobiology of Eating Control: Recent Advances - Oxford Academic, accessed April 22, 2025, pmc.ncbi.nlm.nih.gov, accessed April 22, 2025, Taking a GLP-1